Zymeworks (NASDAQ:ZYME) Raised to “Strong-Buy” at HC Wainwright

Zymeworks (NASDAQ:ZYME) was upgraded by investment analysts at HC Wainwright from a “hold” rating to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

A number of other brokerages have also recently weighed in on ZYME. Wall Street Zen upgraded shares of Zymeworks from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. B. Riley upgraded shares of Zymeworks to a “strong-buy” rating in a report on Thursday, October 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy”.

Zymeworks Stock Up 2.1%

Shares of ZYME stock opened at $18.62 on Tuesday. The firm has a market capitalization of $1.40 billion, a PE ratio of -19.20 and a beta of 1.51. The company has a 50 day simple moving average of $15.50. Zymeworks has a fifty-two week low of $9.03 and a fifty-two week high of $19.50.

Zymeworks (NASDAQ:ZYME) last announced its quarterly earnings data on Tuesday, November 8th. The company reported ($1.14) earnings per share for the quarter. The business had revenue of $4.40 million during the quarter. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.